Humana (NYSE:HUM) has received an average recommendation of “Buy” from the twenty-one analysts that are covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $277.05.
HUM has been the subject of several recent analyst reports. Leerink Swann boosted their target price on Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $297.00 target price for the company in a research report on Monday, January 15th. ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $250.00 price objective on shares of Humana in a report on Wednesday, February 7th. Finally, Oppenheimer upped their price objective on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th.
Humana stock traded down $0.88 during midday trading on Friday, hitting $294.12. 674,199 shares of the company’s stock were exchanged, compared to its average volume of 1,070,938. Humana has a 52-week low of $210.01 and a 52-week high of $299.67. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. The stock has a market cap of $41,071.23, a price-to-earnings ratio of 25.03, a PEG ratio of 1.61 and a beta of 0.97.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The business had revenue of $13.19 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same period in the previous year, the business earned $2.34 earnings per share. The firm’s revenue was up 2.4% on a year-over-year basis. research analysts anticipate that Humana will post 13.86 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 27th. Investors of record on Friday, June 29th will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.68%. Humana’s dividend payout ratio is presently 17.08%.
In related news, insider M Todoroff Christopher sold 16,389 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the completion of the sale, the insider now directly owns 13,447 shares in the company, valued at approximately $3,676,006.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce D. Broussard sold 14,075 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $274.32, for a total value of $3,861,054.00. Following the sale, the chief executive officer now owns 113,896 shares of the company’s stock, valued at $31,243,950.72. The disclosure for this sale can be found here. Insiders have sold a total of 31,660 shares of company stock valued at $8,668,218 over the last 90 days. 0.60% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Prudential Financial Inc. raised its position in Humana by 53.6% during the 3rd quarter. Prudential Financial Inc. now owns 378,133 shares of the insurance provider’s stock valued at $92,125,000 after purchasing an additional 131,990 shares during the last quarter. Eqis Capital Management Inc. raised its position in Humana by 31.5% during the 4th quarter. Eqis Capital Management Inc. now owns 14,132 shares of the insurance provider’s stock valued at $3,506,000 after purchasing an additional 3,385 shares during the last quarter. OppenheimerFunds Inc. raised its position in Humana by 0.4% during the 4th quarter. OppenheimerFunds Inc. now owns 461,589 shares of the insurance provider’s stock valued at $114,507,000 after purchasing an additional 1,771 shares during the last quarter. AMP Capital Investors Ltd raised its position in Humana by 2.5% during the 4th quarter. AMP Capital Investors Ltd now owns 105,243 shares of the insurance provider’s stock valued at $26,108,000 after purchasing an additional 2,532 shares during the last quarter. Finally, Koch Industries Inc. bought a new position in Humana during the 4th quarter valued at approximately $441,000. 96.42% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Humana (HUM) Given Consensus Recommendation of “Buy” by Analysts” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/20/humana-hum-given-consensus-recommendation-of-buy-by-analysts.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.